Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 3
1982 2
1984 2
1985 1
1987 2
1988 3
1990 4
1991 2
1992 3
1993 4
1994 6
1995 4
1996 2
1997 2
1998 3
1999 8
2000 7
2001 4
2002 2
2003 10
2004 11
2005 7
2006 14
2007 16
2008 18
2009 12
2010 14
2011 16
2012 20
2013 13
2014 26
2015 24
2016 20
2017 23
2018 23
2019 30
2020 56
2021 72
2022 53
2023 56
2024 52

Text availability

Article attribute

Article type

Publication date

Search Results

587 results

Results by year

Filters applied: . Clear all
Page 1
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, Pilotto S. Avancini A, et al. Among authors: milella m. Oncologist. 2020 Mar;25(3):e555-e569. doi: 10.1634/theoncologist.2019-0463. Epub 2019 Nov 26. Oncologist. 2020. PMID: 32162811 Free PMC article. Review.
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L, Avancini A, Sposito M, Milella M, Rossi A, Pilotto S. Belluomini L, et al. Among authors: milella m. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3. Expert Opin Biol Ther. 2023. PMID: 36995069 Review.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Among authors: milella m. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
Cutaneous Angiosarcoma.
Roberto S, Riccardo N, Sokol S, Paolo DTA, Marta S, Milella M, Aldo S. Roberto S, et al. Among authors: milella m. JAMA Otolaryngol Head Neck Surg. 2024 Aug 1;150(8):746-748. doi: 10.1001/jamaoto.2024.1715. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38958936
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors.
Pettinella F, Mariotti B, Lattanzi C, Bruderek K, Donini M, Costa S, Marini O, Iannoto G, Gasperini S, Caveggion E, Castellucci M, Calzetti F, Bianchetto-Aguilera F, Gardiman E, Giani M, Dusi S, Cantini M, Vassanelli A, Pavone D, Milella M, Pilotto S, Biondani P, Höing B, Schleupner MC, Hussain T, Hadaschik B, Kaspar C, Visco C, Tecchio C, Koenderman L, Bazzoni F, Tamassia N, Brandau S, Cassatella MA, Scapini P. Pettinella F, et al. Among authors: milella m. Cell Rep Med. 2024 Feb 20;5(2):101380. doi: 10.1016/j.xcrm.2023.101380. Epub 2024 Jan 18. Cell Rep Med. 2024. PMID: 38242120 Free PMC article.
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories.
Sposito M, Belluomini L, Pontolillo L, Tregnago D, Trestini I, Insolda J, Avancini A, Milella M, Bria E, Carbognin L, Pilotto S. Sposito M, et al. Among authors: milella m. J Pers Med. 2023 Sep 22;13(10):1427. doi: 10.3390/jpm13101427. J Pers Med. 2023. PMID: 37888038 Free PMC article. Review.
Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers.
Lasorsa F, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, Autorino R, Battaglia M, Ditonno P, Lucarelli G. Lasorsa F, et al. Among authors: milella m. Int J Mol Sci. 2023 Aug 24;24(17):13179. doi: 10.3390/ijms241713179. Int J Mol Sci. 2023. PMID: 37685983 Free PMC article. Review.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: milella m. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
587 results